Haydon et al., showed that PPARγ agonist, Troglitazone, induced cell differentiation and apoptosis [14]; while Lucarelli et al., provided evidence that Troglitazone increased cell proliferation and inhibited apoptosis in human osteosarcoma cells [30]. This evidence concerns the gene PPARG and osteosarcoma.